A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India

Allergan

Status: Completed

Conditions: Urinary Incontinence; Overactive Bladder

Treatments: Biological: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT02590250

191622-140

Details and patient eligibility

About

This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive bladder.

Enrollment: 250 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with urinary incontinence due to NDO or OAB treated with BOTOX® as per local standard of care in clinical practice.

Exclusion criteria

• None

Trial design

250 participants in 1 patient group

BOTOX®

Description:

Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.

Treatment:

Biological: botulinum toxin Type A